Abstract: A polypeptide selected from the group consisting of BMEII0923, BMEI0411, a protective fragment of BMEII0923 and BMEI0411 and immunologically active variants of BMEII0923 and BMEIO411, which provides a protective immune response against Brucella infection, for use as a vaccine against Brucellosis. Pharmaceutical compositions comprising these polypeptides and antibodies raised against these polypeptides are described and claimed. Such pharmaceutical compositions are useful in both active and passive vaccination against Brucella infections and may be used to treat Brucella infection or Brucellosis after exposure to the bacteria.

Abstract: This invention relates to proteins expressed by ABC system genes of Burkholderia pseudomallei. The proteins (or protective fragments or protective variants thereof) are protective against Burkholderia pseudomallei infection. Use of the proteins in treating Burkholderia mallei or Burkholderia pseudomallei infection and uses in the preparation of vaccines against melioidosis and glanders are described and claimed.

Abstract: A polypeptide derived from the periplasmic space of Yersinia pestis or a fragment or a variant of said polypeptide for use as a medicament is described. Pharmaceutical compositions comprising such polypeptides, such as OppA from Yersinia pestis, are also described and claimed. In a preferred embodiments the pharmaceutical composition further comprises existing protective antigens from Y. pestis such as F1 and V antigens. Such compositions are protective in mice and may be used as a vaccine for the prophylactic or therapeutic treatment of plague.